Cargando…

Diabetic Retinal Neurodegeneration Is Associated With Mitochondrial Oxidative Stress and Is Improved by an Angiotensin Receptor Blocker in a Model Combining Hypertension and Diabetes

OBJECTIVE: Diabetic retinopathy displays the features of a neurodegenerative disease. Oxidative stress is involved in the pathogenesis of diabetic retinopathy. This investigation sought to determine whether hypertension exacerbates the oxidative stress, neurodegeneration, and mitochondrial dysfuncti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Silva, Kamila C., Rosales, Mariana A.B., Biswas, Subrata K., Lopes de Faria, Jose B., Lopes de Faria, Jacqueline M.
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2009
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2682683/ https://www.ncbi.nlm.nih.gov/pubmed/19289456 http://dx.doi.org/10.2337/db09-0166

Ejemplares similares

A decrease in retinal progenitor cells is associated with early features of diabetic retinopathy in a model that combines diabetes and hypertension
por: Lopes de Faria, Jacqueline Mendonça, et al.
Publicado: (2008)

Conditioned Medium from Early-Outgrowth Bone Marrow Cells Is Retinal Protective in Experimental Model of Diabetes
por: Duarte, Diego A., et al.
Publicado: (2016)

Uncoupling Endothelial Nitric Oxide Synthase Is Ameliorated by Green Tea in Experimental Diabetes by Re-establishing Tetrahydrobiopterin Levels
por: Faria, Aline M., et al.
Publicado: (2012)

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
por: Heerspink, H. J. L., et al.
Publicado: (2016)

The use of green tea polyphenols for treating residual albuminuria in diabetic nephropathy: A double-blind randomised clinical trial
por: Borges, Cynthia M., et al.
Publicado: (2016)

The spatial relation of diabetic retinal neurodegeneration with diabetic retinopathy
por: van de Kreeke, Jacoba A., et al.
Publicado: (2020)

The Effect of an Angiotensin Receptor Blocker on Arterial Stiffness in Type 2 Diabetes Mellitus Patients with Hypertension
por: Kim, Ji Hyun, et al.
Publicado: (2011)

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
por: Lee, Hyun Woong
Publicado: (2014)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

Retinal Neurodegeneration in Diabetes: an Emerging Concept in Diabetic Retinopathy
por: Sachdeva, Mira M.
Publicado: (2021)

Renal protection induced by physical exercise may be mediated by the irisin/AMPK axis in diabetic nephropathy
por: Formigari, Guilherme Pedron, et al.
Publicado: (2022)

The Role of Angiotensin Receptor Blockers in the Personalized Management of Diabetic Neuropathy
por: Kostourou, Danai-Thomais, et al.
Publicado: (2022)

Effects of Angiotensin Receptor Blockers on Streptozotocin-Induced Diabetic Cataracts
por: Ishigooka, Gaku, et al.
Publicado: (2023)

Comparative effect of angiotensin II type I receptor blockers and calcium channel blockers on laboratory parameters in hypertensive patients with type 2 diabetes
por: Nishida, Yayoi, et al.
Publicado: (2012)

Renin-angiotensin system blockers regulate the metabolism of isolated fat cells in vitro
por: Caminhotto, R de O., et al.
Publicado: (2016)

The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients: Is there a room for vitamin D?
por: Sukkarieh, Hatouf H., et al.
Publicado: (2020)

Retinal Neurodegeneration in Different Risk Phenotypes of Diabetic Retinal Disease
por: Madeira, Maria H., et al.
Publicado: (2021)

Comment on: The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients. Is there a room for vitamin D?
por: Alsaeed, Abdulghani
Publicado: (2021)

Comment on: The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients. Is there a room for vitamin D?
por: Jawad, Ali S.
Publicado: (2020)

Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15 990 patients
por: Hasvold, L P, et al.
Publicado: (2014)

Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers
por: Konoshita, Tadashi, et al.
Publicado: (2009)

A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy
por: Pathak, Jahnavi V., et al.
Publicado: (2015)

Adding thiazide to a rennin-angiotensin blocker regimen to improve left ventricular relaxation in diabetes and nondiabetes patients with hypertension
por: Takami, Takeshi, et al.
Publicado: (2012)

An increase in mitochondrial TOM activates apoptosis to drive retinal neurodegeneration
por: Periasamy, Agalya, et al.
Publicado: (2022)

Retinal Neurodegeneration in the Course of Diabetes-Pathogenesis and Clinical Perspective
por: Araszkiewicz, Aleksandra, et al.
Publicado: (2016)

rowth Factors in the Pathogenesis of Retinal Neurodegeneration in Diabetes Mellitus
por: Iwona, Ben-Skowronek
Publicado: (2016)

Implications of Diabetes-Induced Altered Metabolites on Retinal Neurodegeneration
por: Aldosari, Dalia I., et al.
Publicado: (2022)

Aliskiren – an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension
por: Zaporowska-Stachowiak, Iwona, et al.
Publicado: (2013)

Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
por: Zhang, Chao, et al.
Publicado: (2021)

Fixed-Dose Combinations of Renin–Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors
por: Hsiao, Fu-Chih, et al.
Publicado: (2015)

Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African‐American patients with hypertension
por: Johnson, Wallace, et al.
Publicado: (2017)

Treatment of hypertension with angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers and resting metabolic rate: A cross‐sectional study
por: Pedrianes‐Martin, Pablo B., et al.
Publicado: (2021)

The Role of Renin–Angiotensin System in Diabetic Cardiomyopathy: A Narrative Review
por: Batista, João Pedro Thimotheo, et al.
Publicado: (2023)

Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan
por: Omboni, Stefano, et al.
Publicado: (2018)

Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension
por: Tian, Ci, et al.
Publicado: (2021)

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and risk of depression among older people with hypertension
por: van Sloten, Thomas T, et al.
Publicado: (2022)

Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney
por: Jiang, Xiao, et al.
Publicado: (2020)

Association of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID‐19
por: Khera, Rohan, et al.
Publicado: (2021)

Letter: The Effect of an Angiotensin Receptor Blocker on Arterial Stiffness in Type 2 Diabetes Mellitus Patients with Hypertension (Diabetes Metab J 2011;35:236-42)
por: Kim, Chul-Hee
Publicado: (2011)

Response: The Effect of an Angiotensin Receptor Blocker on Arterial Stiffness in Type 2 Diabetes Mellitus Patients with Hypertension (Diabetes Metab J 2011;35:236-42)
por: Kim, Ji Hyun, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_u47epcpmfj6ji02cjfcld48tj2